Oregon Public Employees Retirement Fund Reduces Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Oregon Public Employees Retirement Fund reduced its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,350 shares of the specialty pharmaceutical company’s stock after selling 272 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Jazz Pharmaceuticals were worth $1,521,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of JAZZ. IFP Advisors Inc purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth $25,000. UMB Bank n.a. increased its position in Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares in the last quarter. Itau Unibanco Holding S.A. increased its position in Jazz Pharmaceuticals by 63.2% during the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after buying an additional 172 shares in the last quarter. GAMMA Investing LLC increased its position in Jazz Pharmaceuticals by 49.8% during the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 206 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its position in Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after buying an additional 704 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $140.00 to $150.00 in a research report on Wednesday. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Robert W. Baird raised their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Finally, Royal Bank of Canada lowered their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $182.47.

Insider Activity at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 2,000 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the transaction, the chief executive officer now owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. This represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 5,053 shares of company stock valued at $617,442. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Trading Up 0.2 %

NASDAQ:JAZZ opened at $143.53 on Friday. The stock has a market cap of $8.68 billion, a price-to-earnings ratio of 20.22, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The business’s 50-day simple moving average is $126.28 and its 200 day simple moving average is $118.79.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.